<?xml version="1.0" encoding="UTF-8"?>
<ref id="B6">
 <label>6.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Duffy</surname>
    <given-names>N.A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Green</surname>
    <given-names>B.D.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Irwin</surname>
    <given-names>N.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Gault</surname>
    <given-names>V.A.</given-names>
   </name>, 
   <name name-style="western">
    <surname>McKillop</surname>
    <given-names>A.M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>O'Harte</surname>
    <given-names>F.P.</given-names>
   </name>
   <etal>et al</etal>.
  </person-group> (
  <year>2007</year>) 
  <article-title>Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1</article-title>. 
  <source>Eur. J. Pharmacol.</source>
  <volume>568</volume>, 
  <fpage>278</fpage>â€“
  <lpage>286</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ejphar.2007.05.010</pub-id>
  <?supplied-pmid 17573070?>
  <pub-id pub-id-type="pmid">17573070</pub-id>
 </mixed-citation>
</ref>
